Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

This Government Contract opportunity from Department Of Health And Human Services was posted on August 5, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Intent to Sole Source - Hyper-Hypothermia Systems

Closed
NOI-CC-OLAO-26-008665Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

The National Institutes of Health, Clinical Center intends to sole source two Hyper-Hypothermia Systems from Gentherm under a firm-fixed price agreement to support the upcoming Pediatric Intensive Care Unit. These systems, which are programmable temperature management devices using specialized water blankets, are currently in use at the Clinical Center and are essential for precise patient cooling and warming. The contract includes all necessary equipment, parts, labor, travel, training, and on-site installation, with a strict requirement for original equipment manufacturer parts only. The vendor must also provide expert coordination and documentation support in the event of adverse patient incidents. This procurement is justified under 41 U.S.C. 253(c)(1) and FAR 6.302-1, as Gentherm is the only responsible source capable of meeting the agency’s specific technical and operational needs. Although this is not a request for proposal, the government is soliciting capability statements from other potential suppliers through August 10, 2026, at 12:00 PM Eastern Time, to assess whether competition is feasible. All submissions must reference solicitation number NOI-CC-OLAO-26-008665 and be sent to valerie.gregorio@nih.gov. The government retains full discretion to proceed without competition regardless of responses received, and the acquisition falls under NAICS code 339112 with performance located in Bethesda, Maryland.

General Info

Sole source contract for two Hyper-Hypothermia Systems from Gentherm to support Pediatric ICU in Bethesda, Maryland.

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

339112 - Surgical and Medical Instrument ManufacturingView NAICS

Place of Performance

Bethesda, MD, 20892, USA

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

PhaseClosed
Posted

special-notice

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
ContactsNo contacts available
OfficeBethesda, MD, 20892, USA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
View Agency Profile
Office AddressBethesda, MD, 20892, USA
ContactsNo contact information available

Full Description

Show more

This is a Notice of Intent, not a request for proposal.  The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with the following vendor: Gentherm.


Acquisition Description:


Hyper-Hypothermia Systems are programmable patient temperature management devices that precisely controls both cooling and warming using specialized water blankets.


The Clinical Center needs to buy two Hyper-Hypothermia Systems to meet the needs of the soon to be established Pediatric Intensive Care Unit (PICU). The CC currently uses Hyper-Hypothermia Blanketrol® III systems manufactured by Gentherm. These units are used in DPM and the ICU.  This Firm-Fix Price agreement includes all equipment, parts, labor, travel, training and onsite installation. This requirement encompasses only OEM parts. Vendor shall provide expertise to coordinate issues and documentation, in case of adverse patient incidents.


The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.  All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-CC-OLAO-26-008665) by 12:00 PM eastern standard time on 08/10/2026 to: valerie.gregorio@nih.gov.


All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 541715
Federal
National NeuroHIV Tissue Consortium (NNTC) - Clinical Sites
Solicitation # 75N98026R00139
The National Institute of Mental Health plans to modify two existing contracts with the University of California, San Diego and Washington University to increase funding for Task 2 of the National NeuroHIV Tissue Consortium, which supports clinical research on HIV-related neurocognitive and mental health outcomes. The modification to UCSD’s contract will raise its value by $269,941 to $13,774,419, extending performance through August 22, 2027, while WASHU’s contract will increase by $543,301.63 to $8,322,165.63 through September 22, 2027. These adjustments are necessary to sustain critical participant recruitment, clinical assessments, and longitudinal follow-up essential for advancing HIV cure research, particularly through viral reservoir assays and other cure-relevant measures that leverage existing, deeply characterized cohorts. The work also includes the collection, storage, and distribution of central and peripheral nervous system tissues, cerebrospinal fluid, and associated clinical data to a national research community, aligning with the NIMH’s mission to understand how immune dysregulation and psychosocial stress impact brain health. The contracts are sole-source actions authorized under 41 U.S.C. 3304(a)(1) and the Revolutionary FAR Overhaul, as no other entities possess the established infrastructure, participant pools, and neuropsychiatric expertise required to continue this work without disruption. Classified under NAICS code 541715 with a 1,000-employee small business size standard, the effort supports a national resource established in 1998 that provides high-quality biospecimens and clinical data from both HIV-positive and HIV-negative donors. The modification ensures continuity in advancing research on HIV-associated CNS complications, aging with long-term HIV and antiretroviral therapy, and mechanisms underlying neurocognitive decline. While no competitive solicitation will be issued, interested parties may submit capability statements or objections by August 22, 2026, to the Contracting Officer at NIH, with all responses required to include active SAM registration, a Unique Entity Identifier, and Taxpayer Identification Number. The government retains full discretion to proceed non-competitively regardless of received feedback.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

in 3 days
View Details
NAICS: 811210
Federal
Preventative Maintenance Service Contract for the Scan Module LSM 880 Microscope
Solicitation # 75N98026Q00966
The National Institutes of Health intends to award a sole-source preventative maintenance service contract to Carl Zeiss Microscopy for the Scan Module LSM 880 Microscope, serial number 2802000272, an existing government-owned instrument originally manufactured by the same vendor. The contract requires that all maintenance be performed by OEM-certified factory-trained technicians using only OEM-authorized parts, ensuring the highest level of technical compatibility and performance integrity. Due to the proprietary nature of the equipment and the specialized expertise required, Carl Zeiss Microscopy is the only vendor capable of meeting these specifications, justifying the sole-source procurement approach. The solicitation, identified by number 75N98026Q00966, was posted on August 6, 2026, with responses due by August 21, 2026, and the service contract is expected to be awarded around September 15, 2026. The contract falls under NAICS code 811210 for scientific and technical services and will be managed by the National Institutes of Health under the Department of Health and Human Services. Performance is scheduled to occur in Baltimore, Maryland, while the contracting office is located in Bethesda, Maryland. Polina Klimenkova is the point of contact for inquiries, and all necessary details are available through the provided SAM.gov link.
Electronic and Precision Equipment Repair and Maintenance

POSTED

13 days ago

DEADLINE

in 2 days
View Details
NAICS: 541715
SBIR / STTR
Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers.
Solicitation # 2
In the United States, cancer remains the leading cause of death from disease among children aged 1 to 14, with approximately 9,550 cases expected to be diagnosed in 2025 among those under 15. Rare cancers, defined by the FDA as affecting fewer than 200,000 individuals nationwide, are the top cause of cancer-related deaths overall, yet they suffer from drastically underfunded and slow-moving research pipelines due to small patient populations and complex development pathways. This funding opportunity targets innovative, high-risk, and disruptive technologies aimed at preventing, detecting, diagnosing, or treating pediatric and rare cancers, prioritizing bold ideas with strong scientific merit over incremental advances or those relying on preliminary data. Applicants must clearly articulate the clinical unmet need, specify the cancer types addressed using authoritative prevalence data, and design experiments to generate foundational proof-of-concept evidence that de-risks their approach. The NCI SBIR Innovative Concept Award supports small businesses with fewer than 500 employees in developing transformative devices, diagnostic tools, or digital health solutions tailored to these underserved populations. While preliminary data is not required, proposals must be grounded in sound scientific reasoning from published literature or the applicant’s own research. Activities may include early prototype development, phantom and in vivo validation, biomarker optimization, analytic validation of assays, and testing in deidentified clinical samples, depending on the technology type. Beyond technical validation, applicants are expected to explore commercial viability, including business modeling and commercialization strategy, with additional support provided through entrepreneurship training. The goal is to generate actionable data that moves ideas closer to market readiness, culminating in a formal report to the NCI summarizing results and demonstrating technical feasibility. The solicitation is open to small businesses through a total small business set-aside, with proposals due by September 21, 2026.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 1 month ago

DEADLINE

in about 1 month
View Details
NAICS: 541714
SBIR / STTR
Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.
Solicitation # 1
Each year, approximately 9,550 children under 15 in the United States are diagnosed with cancer, making it the leading cause of death from disease in children ages 1 to 14 after infancy, while rare cancers collectively represent the top cause of cancer-related deaths nationwide. Defined by the FDA Orphan Drug Act as malignancies affecting fewer than 200,000 individuals in the U.S., rare cancers and pediatric cancers face significant developmental challenges due to small patient populations and limited clinical data, resulting in slower progress in treatment innovation compared to more common cancers. This initiative seeks bold, high-risk, and transformative technologies—therapies, diagnostics, devices, or preventive strategies—that address critical unmet needs in these underserved areas, with a strong emphasis on disruptive ideas grounded in sound scientific principles rather than incremental improvements. Preliminary data is not required, but proposals must clearly articulate the clinical problem, specify the targeted cancer type supported by authoritative prevalence estimates from sources like SEER, and outline a plausible pathway to meaningful improvement in survival or care. The funding program is designed to support early-stage proof-of-concept research that de-risks innovation, enabling applicants to generate key technical validation data within the award period. Offerors are expected to propose experiments tailored to their technology, such as target validation, lead optimization, in vivo efficacy testing, or preliminary pharmacokinetic studies, and deliver a final report documenting outcomes. In addition to financial support, recipients will receive business and commercialization coaching to refine their business models and explore viable development pathways, with the ultimate goal of translating novel concepts into viable solutions for pediatric and rare cancer patients. This solicitation is exclusively available to small businesses with fewer than 500 employees under a Total Small Business Set-Aside and is open for applications through September 21, 2026.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

about 1 month ago

DEADLINE

in about 1 month
View Details
NAICS: 541519
Federal
Justification for Cancellation of Solicitation No. CS-119444-O
Solicitation # CS-119444-O
The National Institutes of Health, under the Department of Health and Human Services, canceled Solicitation No. CS-119444-O issued through the NITAAC CIO-SP3 GWAC vehicle on June 25, 2026, due to strategic misalignment with the agency’s evolving enterprise IT centralization initiative and updated cybersecurity mandates. The original solicitation sought comprehensive IT services including application modernization, cloud and SharePoint migration, cybersecurity operations, network management, infrastructure support, software development, and PMO oversight, all intended to advance NIH’s digital transformation goals. However, the scope was deemed outdated in light of new federal directives such as Executive Order 14028, OMB M-22-09 on Zero Trust Architecture, and Executive Order 14240, which necessitate a broader, more integrated approach under revised governance frameworks. The cancellation occurred prior to any offeror submissions, evaluations, or award, meaning no pricing, contract value, or performance timelines were established, and no special contract requirements, clauses, or evaluation criteria were finalized or enforced. The place of performance remains Bethesda, Maryland, with the Office of Acquisition and Logistics Management maintaining oversight through Contracting Officer Justin M. Borden. The solicitation was not set aside for any socioeconomic category and was open to all businesses. All intended deliverables, standards, and compliance obligations tied to the original Performance Work Statement are no longer viable, requiring a re-compete under a consolidated IT services vehicle aligned with current federal IT and cybersecurity policies.
Other Computer Related Services

POSTED

about 2 months ago

DEADLINE

N/A
View Details